Designing the right trial for sacubitril / valsartan in heart failure with preserved ejection fraction–related pulmonary hypertension. Authors’ reply | Synapse
March 3, 2026Open Access
Designing the right trial for sacubitril / valsartan in heart failure with preserved ejection fraction–related pulmonary hypertension. Authors’ reply
Key Points
Sacubitril/valsartan may improve outcomes in heart failure with preserved ejection fraction related to pulmonary hypertension.
The proposal emphasizes targeting specific clinical trial designs to effectively assess treatment efficacy.
Observational analysis of ongoing clinical trials highlights a need for precision in outcome measurements related to patient populations.
This approach may enable improved understanding and management of heart failure with pulmonary hypertension in future trials.
Abstract
DOI: 10.20452/pamw.17212, Published online: January 29, 2026, Authors: Małgorzata Niemiec1,2, Marek Grabka1,2, Rafał Niemiec1,2, Artur Filipecki1,2, Mateusz Polak1,2, Katarzyna Mizia-Stec1,2